Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NEOG-100 in Advanced Breast and Lung Cancer
NCT06107894Phase 1Not yet recruiting
- Sponsor
- Neogen Corporation
- Start
- Jan 2024
- Primary completion
- Sep 2025
- Modality
- Tumor-Infiltrating Lymphocytes (TILs)
01
Overview
Phase 1, open-label trial of NEOG-100 in breast cancer and Lung Cancer (LC) (2 arms), sponsored by Neogen Corporation. Primary endpoints: Dose limiting toxicity at 4 weeks, Adverse events at 6 months and 3 more. Planned start Jan 2024; status: not yet recruiting.
02
Drugs
NEOG-100
03
Conditions
breast cancerLung Cancer (LC)
Beyond the preview
Go deeper on NCT06107894.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06107894.